Gavi Filippo, Sighinolfi Maria Chiara, Fettucciari Daniele, Carerj Cristina, Marino Filippo, Panio Enrico, Russo Pierluigi, Foschi Nazario, Bientinesi Riccardo, Gandi Carlo, Palermo Giuseppe, Totaro Angelo, Sacco Emilio, Rocco Bernardo
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Humanitas Gavazzeni, Bergamo, Italy.
World J Urol. 2025 Apr 20;43(1):236. doi: 10.1007/s00345-025-05608-2.
Hugo RAS is a novel robotic platform gaining global adoption. Most reported outcomes come from centers with prior Da Vinci experience, with limited data from robotic-naïve settings or comparisons based on prior robotic expertise.
To compare outcomes of Hugo RAS robot-assisted radical prostatectomy (RARP) performed by Da Vinci-experienced (DVE) versus non-Da Vinci-experienced (NDVE) surgeons.
DESIGN, SETTING, AND PARTICIPANTS: Prospective data from patients undergoing Hugo-RARP (July 2022-November 2024) were analyzed. Patients were grouped based on whether their surgeon had prior Da Vinci experience. None had prior Hugo-RAS experience.
Primary outcomes were positive surgical margin (PSM) and complication rates. Secondary outcomes included operative time (OT), estimated blood loss (EBL), length of stay (LOS), continence, and potency. Propensity score matching adjusted for baseline differences.
After matching, 117 patients per group were analyzed. PSM rates (17% vs. 21%; p = 0.40) and complications (p = 0.63) were similar. DVE surgeons had shorter OT (179 vs. 206 min; p < 0.001) and lower EBL (127 vs. 161 ml; p = 0.008). LOS did not differ (p = 0.84), and 12-month functional and oncological outcomes were comparable. Limitations include the non-randomized, single-center design.
Hugo RAS enables safe and effective RARP with comparable outcomes regardless of prior robotic experience. Prior Da Vinci experience, however, improves intraoperative efficiency.
雨果机器人辅助手术系统(Hugo RAS)是一种正在全球范围内得到应用的新型机器人平台。大多数已报道的结果来自有达芬奇手术系统使用经验的中心,来自初次使用机器人手术环境的数据或基于先前机器人手术专业知识的比较数据有限。
比较由有达芬奇手术系统使用经验(DVE)的外科医生与无达芬奇手术系统使用经验(NDVE)的外科医生进行的雨果机器人辅助根治性前列腺切除术(RARP)的结果。
设计、设置和参与者:分析了接受雨果机器人辅助根治性前列腺切除术(2022年7月至2024年11月)患者的前瞻性数据。根据外科医生是否有达芬奇手术系统使用经验对患者进行分组。所有患者此前均无雨果机器人辅助手术系统使用经验。
主要结果为手术切缘阳性(PSM)率和并发症发生率。次要结果包括手术时间(OT)、估计失血量(EBL)、住院时间(LOS)、控尿和性功能。采用倾向得分匹配法对基线差异进行校正。
匹配后,每组分析117例患者。手术切缘阳性率(17%对21%;p = 0.40)和并发症发生率(p = 0.63)相似。有达芬奇手术系统使用经验的外科医生手术时间较短(179对206分钟;p < 0.001),估计失血量较低(127对161毫升;p = 0.008)。住院时间无差异(p = 0.84),12个月时的功能和肿瘤学结果具有可比性。局限性包括非随机、单中心设计。
无论先前有无机器人手术经验,雨果机器人辅助手术系统均可实现安全有效的根治性前列腺切除术,结果相当。然而,先前的达芬奇手术系统使用经验可提高术中效率。